Q-omics provides the consensus-scored PROX2 profile across patient tissues and cancer cell-line models. PROX2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, PROX2 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, PROX2 RNA expression shows 19,602 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BRCA, HNSC, and THYM as cancer lineages where PROX2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PROX2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PROX2 survival associations across molecular data types. PROX2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PROX2 RNA expression–survival associations across cancer types. High PROX2 expression shows unfavorable associations in MESO, but favorable associations in BRCA, BLCA, ESCA, SKCM and CHOL. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for PROX2 RNA expression.
This table summarizes PROX2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for PROX2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PROX2 shows lower tumor expression in BRCA and THCA and higher tumor expression in HNSC, CHOL, KICH and LIHC. The HNSC box plot shows higher PROX2 RNA expression in tumor versus normal tissue (log2 FC = +0.085, t-test p < 0.001).
This table shows molecular features associated with PROX2 in patient tissues and cancer cell lines. In patient samples, PROX2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PROX2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
